About Freenome
Outpacing cancer starts with early detection
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Brisbane, California
- Founded
- 2014
- Company type
- Privately Held
Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.
Specialties
- molecular diagnostics
- multiomics
- machine learning
- biotechnology
- cancer screening
- oncology
- early cancer detection
- and computational biology
Company locations
3300 Marina Blvd, Brisbane, California 94005, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 46,076
- People linked to this company
- 395
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.